Cargando…

Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

OBJECTIVE: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Linares, Ila M., Zuardi, Antonio W., Pereira, Luis C., Queiroz, Regina H., Mechoulam, Raphael, Guimarães, Francisco S., Crippa, José A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Psiquiatria 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781714/
https://www.ncbi.nlm.nih.gov/pubmed/30328956
http://dx.doi.org/10.1590/1516-4446-2017-0015
_version_ 1783457425881300992
author Linares, Ila M.
Zuardi, Antonio W.
Pereira, Luis C.
Queiroz, Regina H.
Mechoulam, Raphael
Guimarães, Francisco S.
Crippa, José A.
author_facet Linares, Ila M.
Zuardi, Antonio W.
Pereira, Luis C.
Queiroz, Regina H.
Mechoulam, Raphael
Guimarães, Francisco S.
Crippa, José A.
author_sort Linares, Ila M.
collection PubMed
description OBJECTIVE: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method. METHOD: A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in a double-blind procedure. During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points. RESULTS: Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo. CONCLUSION: Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves. Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice.
format Online
Article
Text
id pubmed-6781714
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Associação Brasileira de Psiquiatria
record_format MEDLINE/PubMed
spelling pubmed-67817142019-10-25 Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test Linares, Ila M. Zuardi, Antonio W. Pereira, Luis C. Queiroz, Regina H. Mechoulam, Raphael Guimarães, Francisco S. Crippa, José A. Braz J Psychiatry Original Article OBJECTIVE: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method. METHOD: A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in a double-blind procedure. During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points. RESULTS: Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo. CONCLUSION: Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves. Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice. Associação Brasileira de Psiquiatria 2018-10-11 /pmc/articles/PMC6781714/ /pubmed/30328956 http://dx.doi.org/10.1590/1516-4446-2017-0015 Text en http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Linares, Ila M.
Zuardi, Antonio W.
Pereira, Luis C.
Queiroz, Regina H.
Mechoulam, Raphael
Guimarães, Francisco S.
Crippa, José A.
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_full Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_fullStr Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_full_unstemmed Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_short Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_sort cannabidiol presents an inverted u-shaped dose-response curve in a simulated public speaking test
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781714/
https://www.ncbi.nlm.nih.gov/pubmed/30328956
http://dx.doi.org/10.1590/1516-4446-2017-0015
work_keys_str_mv AT linaresilam cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT zuardiantoniow cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT pereiraluisc cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT queirozreginah cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT mechoulamraphael cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT guimaraesfranciscos cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT crippajosea cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest